Health and Healthcare
4 Speculative Biotech and Biohealth Analyst Upgrades
Published:
Last Updated:
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. But 2017 could be different, with a new administration and new perspective that could lead to more positive trials, U.S. Food and Drug Administration (FDA) approvals and mergers and acquisitions.
It seems that analysts are taking the forefront and making calls on where the biopharma industry is going ahead of action by the Trump administration. 24/7 Wall St. has collected a few of the important calls on the day thus far and added some color on them.
We have included what analysts are saying about each stock, as well as a recent trading history and the consensus price target.
Alynylam Pharmaceuticals Inc. (NASDAQ: ALNY) was upgraded by JPMorgan to a Neutral rating, and the price target was raised to $53 from $50. The stock had previously closed at $38.16. Shares of Alynylam were trading down 3.0% at $37.01 midday Tuesday, with a consensus analyst price target of $63.36 and a 52-week trading range of $31.38 to $80.11.
Baird raised its rating on Amicus Therapeutics Inc. (NASDAQ: FOLD) to Outperform, while its price target saw a significant gain to $10 from $7. The prior close was $5.34. Shares were trading down 1.8% at $5.24. The consensus price target is $10.69, and a 52-week range is $4.41 to $9.83.
Citigroup upgraded Calithera Biosciences Inc. (NASDAQ: CALA) to Neutral from Sell. The price target was also raised to $5 from $1, compared with a prior close of $4.40. Calithera Biosciences was up 5.7% at $4.65, within a 52-week range of $2.20 to $6.87. The consensus analyst target is $8.25.
Needham issued a Buy rating for GenMark Diagnostics Inc. (NASDAQ: GNMK) and raised its price target to $15, up from $13. The stock had previously closed at $12.48. The shares traded down fractionally to $12.49. The 52-week range is $4.20 to $13.43. The consensus price target is $14.90.
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
